{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:10:38Z","timestamp":1778217038184,"version":"3.51.4"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Breast cancer is the most common malignancy among women worldwide, and endocrine therapy (ET) is crucial for reducing recurrence and mortality in hormone receptor\u2013positive cases. However, ET is often associated with adverse effects, especially musculoskeletal symptoms (MSS) such as arthralgia and myalgia, which impair daily functioning, decrease quality of life, and lead to early therapy discontinuation. Although some pharmacological and non-pharmacological options are available for managing ET-induced MSS, their effectiveness is limited, and so far, no general recommendations exist. In the context of integrative oncology, which combines conventional and complementary approaches, anthroposophic medicine has been proposed as a supportive strategy to address these challenges. This case series investigated the potential of the anthroposophic medicinal product\n                    <jats:italic>Arnica\/Levisticum 6x comp.<\/jats:italic>\n                    for alleviating ET-induced MSS. Three patients with hormone receptor-positive breast cancer, all undergoing ET and experiencing significant MSS unresponsive to conventional management, were included. Clinical data were collected over at least three years of follow-up. The severity of musculoskeletal pain was evaluated using patient reporting and a visual analogue scale (VAS). All three patients reported marked and rapid improvement in ET-associated MSS after beginning treatment with\n                    <jats:italic>Arnica\/Levisticum 6x comp<\/jats:italic>\n                    . Symptom relief was typically achieved within weeks, with an average reduction of 2\u20134 points on the VAS. Notably, symptom recurrence was observed during periods of medication interruption, and symptoms consistently resolved upon reintroduction of\n                    <jats:italic>Arnica\/Levisticum 6x comp.<\/jats:italic>\n                    , suggesting a beneficial therapeutic effect. Throughout the observation period, the medication was well tolerated, with no adverse effects reported. Patients experienced improvements in daily functioning and overall quality of life, which facilitated continued adherence to ET. This case series provides preliminary evidence for the effectiveness and safety of\n                    <jats:italic>Arnica\/Levisticum 6x comp.<\/jats:italic>\n                    as a therapeutic option for managing ET-induced MSS in breast cancer patients. The sustained symptom relief, favorable tolerability, and long-term safety suggest that this anthroposophic medication may serve as a useful adjunct in supportive care, improving quality of life and promoting continued adherence to ET.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1758527","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T04:34:17Z","timestamp":1778214857000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Arnica\/Levisticum 6x comp. can alleviate musculoskeletal symptoms in breast cancer patients undergoing endocrine therapy: a case series"],"prefix":"10.3389","volume":"16","author":[{"given":"Silvia T.","family":"Erni","sequence":"first","affiliation":[{"name":"Institute of Complementary and Integrative Medicine, University of Bern","place":["Bern, Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Ertl","sequence":"additional","affiliation":[{"name":"Institute of Complementary and Integrative Medicine, University of Bern","place":["Bern, Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9lo\u00efse","family":"May","sequence":"additional","affiliation":[{"name":"Institute of Complementary and Integrative Medicine, University of Bern","place":["Bern, Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Grossmann","sequence":"additional","affiliation":[{"name":"Institute of Complementary and Integrative Medicine, University of Bern","place":["Bern, Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursula","family":"Wolf","sequence":"additional","affiliation":[{"name":"Institute of Complementary and Integrative Medicine, University of Bern","place":["Bern, Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.32604\/ONCOLOGIE.2022.027640","article-title":"Epidemiology of breast cancer","volume":"24","author":"Shang","year":"2022","journal-title":"Oncologie"},{"key":"B2","doi-asserted-by":"publisher","first-page":"594","DOI":"10.6004\/JNCCN.2023.0031","article-title":"NCCN guidelines\u00ae Insights: breast cancer, version 4.2023","volume":"21","author":"Gradishar","year":"2023","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"key":"B3","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/JAMA.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials","volume":"378","author":"Godwin","year":"2011","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0261","article-title":"Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer","volume":"30","author":"Henry","year":"2012","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/S10549-006-9193-0","article-title":"Adherence to tamoxifen over the five-year course","volume":"99","author":"Lash","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.07.071","article-title":"Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer","volume":"21","author":"Partridge","year":"2003","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.10.7573","article-title":"Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer","volume":"25","author":"Crew","year":"2007","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/BCR2818","article-title":"Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management","volume":"13","author":"Gaillard","year":"2011","journal-title":"Breast Cancer Research: BCR"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz298","article-title":"Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis","volume":"30","author":"Ferreira","year":"2019","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2016.01.006","article-title":"Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - meta-analyses on efficacy and adverse events based on randomized clinical trials","volume":"26","author":"Ryd\u00e9n","year":"2016","journal-title":"Breast"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1200\/JCO.2015.63.8619","article-title":"Treatment adherence and its impact on disease-free survival in the Breast International Group 1\u201398 trial of tamoxifen and letrozole, alone and in sequence","volume":"34","author":"Chirgwin","year":"2016","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/J.PEC.2024.108349","article-title":"Sticking to the script: breast cancer patients\u2019 decision making regarding oral endocrine therapy","volume":"127","author":"Wheeler","year":"2024","journal-title":"Patient Educ Couns"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2010.03.012","article-title":"Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer","volume":"66","author":"Nogues","year":"2010","journal-title":"Maturitas"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/S10549-011-1644-6","article-title":"Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial","volume":"129","author":"Rastelli","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/S00520-012-1628-Z","article-title":"Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer","volume":"21","author":"Greenlee","year":"2013","journal-title":"Supportive Care Cancer: Off J Multinational Assoc Supportive Care Cancer"},{"key":"B17","article-title":"Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer","volume":"32","author":"Kubo","year":"2012","journal-title":"Anticancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1177\/21649561211073079","article-title":"Anthroposophic medicinal products: a literature review of features, similarities and differences to conventional medicinal products, scientific and regulatory assessment","volume":"11","author":"Baars","year":"2022","journal-title":"Global Adv Health Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2017.04.026","article-title":"CARE guidelines for case reports: explanation and elaboration document","volume":"89","author":"Riley","year":"2017","journal-title":"J Clin Epidemiol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1103507","article-title":"Exemestane for breast-cancer prevention in postmenopausal women","volume":"364","author":"Goss","year":"2011","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/01.BLO.0000092981.12414.7B","article-title":"Metastatic breast cancer: overview of treatment","volume":"415","author":"Ali","year":"2003","journal-title":"Clin Orthopaedics Related Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.mayocp.2018.03.025","article-title":"Updates in the evaluation and management of breast cancer","volume":"93","author":"O\u2019Sullivan","year":"2018","journal-title":"Mayo Clinic Proc"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/S00520-017-3613-Z","article-title":"Prevalence of aromatase inhibitor-induced arthralgia in breast cancer: a systematic review and meta-analysis","volume":"25","author":"Beckw\u00e9e","year":"2017","journal-title":"Supportive Care Cancer: Off J Multinational Assoc Supportive Care Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1177\/20503121221078722","article-title":"Aromatase inhibitor-associated musculoskeletal pain: an overview of pathophysiology and treatment modalities","volume":"10","author":"Grigorian","year":"2022","journal-title":"SAGE Open Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt037","article-title":"Aromatase inhibitor-induced arthralgia: a review","volume":"24","author":"Niravath","year":"2013","journal-title":"Ann Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/J.CRITREVONC.2017.01.010","article-title":"Management of aromatase inhibitor induced musculoskeletal symptoms in postmenopausal early breast cancer: a systematic review and meta-analysis","volume":"111","author":"Roberts","year":"2017","journal-title":"Crit Rev Oncology\/Hematology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/J.PAIN.2009.08.019","article-title":"Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations","volume":"146","author":"Dworkin","year":"2009","journal-title":"Pain"},{"key":"B29","unstructured":"Anthroposophic pharmaceutical codex APC\n          \n          \n          \n          2013"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1515\/bchm.1997.378.9.951","article-title":"Helenalin, an anti-inflammatory sesquiterpene lactone from Arnica, selectively inhibits transcription factor NF-kappaB","volume":"378","author":"Lyss","year":"1997","journal-title":"Biol Chem"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2023.117064","article-title":"Anti-inflammatory effects of Arnica montana (mother tincture and homeopathic dilutions) in various cell models","volume":"318","author":"Verre","year":"2024","journal-title":"J Ethnopharmacol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/917541","article-title":"Inflammatory process modulation by homeopathic Arnica montana 6CH: the role of individual variation","volume":"2011","author":"Kawakami","year":"2011","journal-title":"Evidence-Based Complementary Altern Medicine: ECAM"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2010.06.006","article-title":"The nociceptive and anti-nociceptive effects of bee venom injection and therapy: a double-edged sword","volume":"92","author":"Chen","year":"2010","journal-title":"Prog Neurobiol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2007.04.004","article-title":"Therapeutic application of anti-arthritis, pain-releasing, and anti-cancer effects of bee venom and its constituent compounds","volume":"115","author":"Son","year":"2007","journal-title":"Pharmacol Ther"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/separations12040079","article-title":"Determination of the phytochemical profile and antioxidant activity of some alcoholic extracts of Levisticum officinale with pharmaceutical and cosmetic applications","volume":"12","author":"Sahlabgi","year":"2025","journal-title":"Separations"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(99)00161-X","article-title":"Accuracy of recall of usual pain intensity in back pain patients","volume":"83","author":"Bolton","year":"1999","journal-title":"Pain"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/CNCR.28016","article-title":"Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort","volume":"119","author":"Castel","year":"2013","journal-title":"Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/J.BREAST.2019.12.017","article-title":"Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients","volume":"50","author":"Hack","year":"2020","journal-title":"Breast: Off J Eur Soc Mastology"},{"key":"B39","volume-title":"Musculoskeletal symptoms with endocrine therapy for breast cancer: trajectory and predictors","author":"Zhu","year":"2019"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/J.PAIN.2006.04.005","article-title":"How prior experience shapes placebo analgesia","volume":"124","author":"Colloca","year":"2006","journal-title":"Pain"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1758527\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T04:34:41Z","timestamp":1778214881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1758527\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":40,"alternative-id":["10.3389\/fonc.2026.1758527"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1758527","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"article-number":"1758527"}}